Table of Contents Author Guidelines Submit a Manuscript
International Journal of Medicinal Chemistry
Volume 2012 (2012), Article ID 412614, 6 pages
http://dx.doi.org/10.1155/2012/412614
Research Article

Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors

1Department of Medicinal Chemistry, MethylGene Inc., 7150 Rue Frederick-Banting, Suite 200, Montréal, QC, Canada H4S 2A1
2Department of Cell Biology and Pharmacology, MethylGene Inc., 7150 Rue Frederick-Banting, Suite 200, Montréal, QC, Canada H4S 2A1
3Department of PK/Analytical Chemistry, MethylGene Inc., 7150 Rue Frederick-Banting, Suite 200, Montréal, QC, Canada H4S 2A1

Received 5 December 2011; Revised 13 February 2012; Accepted 13 February 2012

Academic Editor: O. Bruno

Copyright © 2012 Stéphane L. Raeppel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Patapoutian and L. F. Reichardt, “Trk receptors: mediators of neurotrophin action,” Current Opinion in Neurobiology, vol. 11, no. 3, pp. 272–280, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. E. J. Huang and L. F. Reichardt, “Trk receptors: roles in neuronal signal transduction,” Annual Review of Biochemistry, vol. 72, pp. 609–642, 2003. View at Publisher · View at Google Scholar
  3. L. F. Reichardt, “Neurotrophin-regulated signalling pathways,” Philosophical Transactions of the Royal Society B, vol. 361, no. 1473, pp. 1545–1564, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. D. Skaper, “The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors,” CNS and Neurological Disorders - Drug Targets, vol. 7, no. 1, pp. 46–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. G. M. Brodeur, J. E. Minturn, R. Ho et al., “Trk receptor expression and inhibition in neuroblastomas,” Clinical Cancer Research, vol. 15, no. 10, pp. 3244–3250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. J. Thiele, Z. Li, and A. E. McKee, “On Trk—the TrkB signal transduction pathway is an increasingly important target in cancer biology,” Clinical Cancer Research, vol. 15, no. 19, pp. 5962–5967, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. L. Hudkins and K. A. Josef, “Pyrazole trk kinase inhibitors for the treatment of cancer,” Expert Opinion on Therapeutic Patents, vol. 17, no. 3, pp. 351–356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Wang, D. Yu, and M. L. Lamb, “Trk kinase inhibitors as new treatments for cancer and pain,” Expert Opinion on Therapeutic Patents, vol. 19, no. 3, pp. 305–319, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. K. J. Martin, N. Shpiro, R. Traynor, M. Elliott, and J. S. C. Arthur, “Comparison of the specificity of Trk inhibitors in recombinant and neuronal assays,” Neuropharmacology, vol. 61, no. 1-2, pp. 148–155, 2011. View at Publisher · View at Google Scholar
  10. S. J. Miknyoczki, H. Chang, A. Klein-Szanto, C. A. Dionne, and B. A. Ruggeri, “The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma,” Clinical Cancer Research, vol. 5, no. 8, pp. 2205–2212, 1999. View at Google Scholar · View at Scopus
  11. D. E. Gingrich, S. X. Yang, G. W. Gessner, T. S. Angeles, and R. L. Hudkins, “Synthesis, modeling, and in vitro activity of (3′S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3′-sugar alcohol on trkA tyrosine kinase activity,” Journal of Medicinal Chemistry, vol. 48, no. 11, pp. 3776–3783, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Tripathy, T. S. Angeles, S. X. Yang, and J. P. Mallamo, “TrkA kinase inhibitors from a library of modified and isosteric Staurosporine aglycone,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 12, pp. 3551–3555, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Pagano, E. Y. Wong, T. Breiding et al., “From imide to lactam metallo-pyridocarbazoles: distinct scaffolds for the design of selective protein kinase inhibitors,” Journal of Organic Chemistry, vol. 74, no. 23, pp. 8997–9009, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. E. R. Wood, L. Kuyper, K. G. Petrov, R. N. Hunter, P. A. Harris, and K. Lackey, “Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 4, pp. 953–957, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Lippa, J. Morris, M. Corbett et al., “Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 13, pp. 3444–3448, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. H. Kim, J. S. Tokarski, K. J. Leavitt et al., “Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 2, pp. 634–639, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Wang, M. L. Lamb, D. A. Scott et al., “Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases,” Journal of Medicinal Chemistry, vol. 51, no. 15, pp. 4672–4684, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Thress, T. MacIntyre, H. Wang et al., “Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway,” Molecular Cancer Therapeutics, vol. 8, no. 7, pp. 1818–1827, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Raeppel, S. Claridge, O. Saavedra et al., “N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 5, pp. 1323–1328, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Mannion, S. Raeppel, S. Claridge et al., “N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 23, pp. 6552–6556, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Raeppel, O. Saavedra, S. Claridge et al., “Kinase inhibitors and uses thereof,” Patent application WO 2008/046216.